Trial Profile

A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; Abacavir; Emtricitabine; Enfuvirtide; Lamivudine; Tenofovir disoproxil fumarate
Indications HIV-1 infections; Liver transplant rejection
Focus Pharmacokinetics
Acronyms LIVERAL; LIVERAL-ANRS 148

17 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
22 May 2012 Actual patient number 13 added as reported by ClinicalTrials.gov.
22 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com